STOCK TITAN

NanoViricides may sell up to $8.38M in common stock

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B5

Rhea-AI Filing Summary

NanoViricides, Inc. (NNVC) may currently offer and sell common stock with an aggregate offering price of up to $8,376,444 through or to D. Boral Capital LLC under its at-the-market program; D. Boral Capital may act as sales agent or principal. NNVC reported approximately $6,016,722 of shares offered and sold pursuant to General Instruction I.B.6 during the prior 12-calendar-month period ending November 17, 2026.

As of October 19, 2026, NNVC’s public float was $43,179,500. While the public float remains below $75 million, Form S-3 General Instruction I.B.6 limits public primary offerings to one-third of the public float in any 12-calendar-month period. If a higher public float permits additional sales, NNVC will file another amendment before making them.

Aggregate offering price Up to $8,376,444 Common stock NNVC may currently offer and sell through or to D. Boral Capital LLC under the at-the-market program.
Prior 12-month sales Approximately $6,016,722 Shares offered and sold pursuant to General Instruction I.B.6 during the prior 12-calendar-month period ending November 17, 2026.
Public float $43,179,500 Aggregate market value of common stock held by non-affiliates as of October 19, 2026.
Non-affiliate shares outstanding 25,550,000 shares Shares held by non-affiliates as of October 19, 2026, used to calculate public float.
Closing sale price $1.69 per share Common stock closing sale price on September 21, 2026, used to calculate public float.
Public primary offering limit One-third of public float Limit for any 12-calendar-month period while public float remains below $75 million, under General Instruction I.B.6 of Form S-3.
Public float threshold $75 million The one-third public-float limit applies while NNVC’s public float remains below this threshold.
at the market offering financial
"previously announced at the market offering program"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
public float financial
"aggregate market value of our common stock held by non-affiliates, or the public float"
Public float is the total number of a company's shares that are available for trading by the general public. It excludes shares held by company insiders or large stakeholders who are unlikely to sell them easily. This figure helps investors understand how much of the company's stock is actively available, which can influence its liquidity and how easily its price might change.
General Instruction I.B.6 regulatory
"pursuant to General Instruction I.B.6 of Form S-3"
aggregate offering price financial
"having an aggregate offering price of up to $8,376,444"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
Offering Type ATM
Securities Offered Common stock
Offering Amount Up to $8,376,444 aggregate offering price

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much common stock can NNVC sell under its at-the-market program?

NNVC may currently offer and sell common stock with an aggregate offering price of up to $8,376,444 through or to D. Boral Capital LLC under the at-the-market program, with the firm acting as sales agent or principal.

What limits additional NNVC at-the-market sales?

While NNVC’s public float remains below $75 million, public primary offerings under Form S-3 may not exceed one-third of public float in any 12-calendar-month period. If a higher float permits additional sales, NNVC will file another amendment before those sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

AMENDMENT NO. 3 DATED NOVEMBER 17, 2026
To Prospectus Supplement dated July 17, 2026
(To Prospectus Dated June 15, 2026)
Filed pursuant to Rule 424(b)(5)
Registration No. 333-296550

 

 

 

NANOVIRICIDES, INC.

 

Up to $8,376,444

Common Stock

 

 

This Amendment No. 3 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus, dated June 15, 2026 (the “Prospectus”), and the prospectus supplement, dated July 17, 2026 and amended on July 27, 2026 (the “Prospectus Supplement”), which was filed pursuant to our registration statement on Form S-3 (File No. 333-296550) (the “Registration Statement”). This Amendment should be read in conjunction with the Prospectus and Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus and the Prospectus Supplement. This Amendment is not complete without, and may only be delivered or utilized in connection with, the Prospectus and Prospectus Supplement, and any future amendments or supplements thereto.

 

This Amendment is being filed in connection with our previously announced “at the market offering” program, and to update the maximum amount of shares of our common stock, par value $0.00001 per share, that we may issue and sell from time to time through or to D. Boral Capital LLC (the “Agent”) as sales agent or principal, pursuant to the terms of our previously announced At Market Issuance Sales Agreement, dated July 17, 2026, between us and the Agent (the “Sales Agreement”).

 

Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “NNVC”. As of October 19, 2026, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form S-3 was $43,179,500, which was calculated based on 25,550,000 shares of our common stock outstanding held by non-affiliates as of October 19, 2026 at a price of $1.69 per share, the closing sale price for our common stock on September 21, 2026. As of the date hereof, we have offered and sold approximately $6,016,722 of shares of our common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.6) in any 12-calendar month period so long as our public float remains below $75 million.

 

We are filing this Amendment to amend the Prospectus Supplement to update the maximum amount we are eligible to sell under our Registration Statement pursuant to General Instruction I.B.6 of Form S-3. Accordingly, in accordance with the terms of the Sales Agreement, we may currently offer and sell common stock through or to the Agent having an aggregate offering price of up to $8,376,444 pursuant to the Prospectus and Prospectus Supplement, as amended by this Amendment. In the event that our public float increases such that we may sell additional amounts under the Sales Agreement, Prospectus and Prospectus Supplement, we will file another amendment to the Prospectus Supplement prior to making additional sales.

 

 

 

 

Investing in our common stock involves risks. You should carefully consider the risks described under “Risk Factors” in the Prospectus and Prospectus Supplement, as well as those described in our other reports and documents we filed with the Securities and Exchange Commission (the “SEC”) that we incorporate by reference in the Prospectus, the Prospectus Supplement and this Amendment, before making a decision to invest in our common stock.

 

Neither the SEC, any state securities commission, nor any other regulatory body has approved or disapproved of these securities or determined if this Amendment is accurate or complete. Any representation to the contrary is a criminal offense.

 

 

The date of this Amendment No. 3 to Prospectus Supplement is November 17, 2026.

 

 

 

Keep reading